Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 14/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11046570 | 0.95 | CYP1A2 (0.40) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10972196 | 0.93 | SLC29A1 (0.40) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11049547 | 0.93 | SLC29A1 (0.40) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11052740 | 0.92 | KCNH3 (0.39) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10970925 | 0.92 | SLC29A1 (0.43) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11029641 | 0.92 | PDE4A (0.42) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11026335 | 0.92 | PDE4A (0.44) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11032824 | 0.91 | SLC29A1 (0.43) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11049628 | 0.91 | SLC29A1 (0.43) | SLC29A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11028181 | 0.91 | SLC29A1 (0.43) | SLC29A1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0055444-B1 | TRISUBSTITUTED PYRIMIDO(5,4-D)PYRIMIDINES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1985-03-20 | — | — | EP | claimed |
| US-4478833-A | ANTICOAGULANTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-23 | — | — | US | claimed |
| EP-0055444-A2 | Trisubstituted pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1982-07-07 | — | — | EP | claimed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| EP-0055444-B1 | TRISUBSTITUTED PYRIMIDO(5,4-D)PYRIMIDINES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1985-03-20 | — | — | EP | disclosed |
| US-4478833-A | ANTICOAGULANTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-23 | — | — | US | disclosed |
| EP-0055444-A2 | Trisubstituted pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | SLC29A1 3650/4885PDE4A 106/4885PDE4B 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.